Over the past few years, the financial industry has undergone significant transformation as a result of a flurry of technological advancements.This examination of the most recent innovations that have altered the financial landscape focuses on fintech, blockchain technology, artificial intelligence (AI), and digital currencies.Startups in the fintech sector have created brand-new financial services with the goal of improving customer service, efficiency, and accessibility.Block chain technology has revolutionized data management and secure transactions, paving the way for decentralized finance (DeFi) and smart contracts.AI has improved risk assessment, fraud detection, and personalized financial services through advanced data analytics.Digital currencies, particularly crypto currencies and central bank digital currencies (CBDCs), have also challenged conventional monetary systems and introduced new paradigms for global financial transactions.Consumers, regulators, and financial institutions face both challenges and opportunities as a result of these innovations, according to this research.To fully utilize these technologies' potential and address associated risks, the findings emphasize the need for industry-wide adaptation and ongoing collaboration.
After completing his MD at Saint Louis University School of Medicine in Missouri, he completed a basic surgery residency at the University of Chicago Hospital and Clinics and a general surgery residency at Rush–Presbyterian–St. Luke’s Medical Center, also in Chicago, Illinois. “I became interested in oncology about halfway through my residency in surgery,” he says. “I originally thought I would go into burn surgery, which connected with my interest in reconstructive surgery, but when I actually had the opportunity to [work in] a burn unit as a resident, I found that it didn’t address some of my needs. It didn’t speak to the fact that I was spending 5 years in a general surgery residency acquiring knowledge and skills to perform intra-abdominal surgery. I hadn’t initially thought about oncology, but as I started to participate in cancer care as a surgical trainee and began going to the conferences and tumor boards, I came to appreciate how much was not known.” The idea of multidisciplinary teamwork in the oncology field also appealed to him. After a fellowship in surgical oncology at The University of Texas MD Anderson Cancer Center in Houston, Dr. Pollock stayed on as a faculty member, rose through the ranks in the Department of Surgical Oncology, and become a professor and chairman of the department from 1994 to 2010. “I enjoyed the opportunity to build and expand the Department of Surgical Oncology from 8 to 36 faculty members over a decade-plus period of time,” he says. From 1997 to 2012, Dr. Pollock was also professor and head of the Division of Surgery (which includes all 7 surgical specialty departments) at MD Anderson. In 2013, he was recruited and served as professor and director of the Division of Surgical Oncology and chief of surgical services at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University in Columbus. “The James Cancer Hospital was undergoing a major expansion at that time. It gave me the opportunity to participate in planning a complete global cancer surgery environment in a cancer-dedicated hospital,” he says. “I was able to move my lab as well.” Shortly before leaving MD Anderson, a Specialized Program of Research Excellence grant to study sarcoma was awarded by the National Cancer Institute, and he was able to move his components to Ohio. Ohio State University Comprehensive Cancer Center. During his tenure, he has instituted new projects, including the Pelotonia Institute of Immuno-Oncology and a Center for Cancer Engineering. Dr. Pollock’s own research, which falls under the Center for Cancer Engineering, examines exosomes, which are tiny bilipid packets containing DNA, RNA, micro-RNA, and proteins that are released into the circulation.1 “We were very interested in how these [exosomes] might participate in triggering metastatic activity in dedifferentiated liposarcoma, which is a very lethal sarcoma subtype,” says Dr. Pollock. “Working with College of Engineering colleagues, we have developed a small microfluidic-based device that is very useful for isolating these circulating exosomes. It is the size of a cigarette lighter and is now being examined for patentability.” As director of The Ohio State University Comprehensive Cancer Center, Dr. Pollock and his colleagues are also developing a Center for Translational Genomics and a Center for Cancer Prevention and Survivorship. He has served on various committees, working groups, and editorial advisory boards, including as editor-in-chief of Cancer from 2000 to 2011. “Serving as editor-in-chief of Cancer, a journal of the American Cancer Society (ACS), was a remarkable learning experience for me while helping the journal, with the support of ACS leadership, to revamp its operating strategies,” he says. “The editorial board was expanded by recruiting diseaseand process-specific associate editors, we instituted an early adaptation of electronic manuscript submission and evaluation, and we decentralized decision-making to the associate editors. As a result of these team-based changes, the Cancer impact factor quickly rose to new heights.” The bulk of Dr. Pollock’s research has been on sarcoma. “We focused on the molecular biology of sarcoma starting in the early 1990s. As a surgeon, harvesting sarcoma tissues almost daily, I felt there was a moral imperative to study those tissues, with patient consent and participation, and to try to learn more about this biology on the premise that this would, in turn, lead to better therapeutics,” he says. Dr. Pollock’s first exposure to this research came during his fellowship at MD Anderson. He focused on natural killer (NK) cells that have the unusual ability to attack bacteria, viruses, and tumor cells in the circulation. At the end of his fellowship, he applied for and won a National Cancer Institute K08 Clinician-Investigator Award. As a K08 grant recipient, he decided to go to graduate school to earn his PhD at The University of Texas Graduate School of Biological Sciences in Austin. “The entire time I was a grant recipient, I was a fulltime graduate student and a full-time assistant professor of surgery. It was 7 years of 100-hour weeks, but in the long run, it was definitely worth it because the scientific training ultimately enabled me to move from studying NK cell tumor immunology to the molecular biology of sarcoma,” says Dr. Pollock. During his time as chair of the Department of Surgical Oncology at MD Anderson, Dr. Pollock focused his laboratory efforts on the molecular biology of sarcoma, in particular the role of the p53 tumor suppressor gene in sarcoma oncobiology.2 During this time, he met and married surgical oncologist Dina Chelouche Lev, MD; they operated a shared sarcoma research program for almost 15 years until her untimely death in 2020. Six years ago, Dr. Pollock was diagnosed with chronic lymphocytic leukemia. “I hadn’t initially thought about oncology, but as I started to participate in cancer care as a surgical trainee and began going to the conferences and tumor boards, I came to appreciate how much was not known.” —Raphael Pollock, MD, PhD into the circulation, and we’ve been able to show how these exosomes interact with the cells in the tumor microenvironment, especially macrophages and preadipocytes,” he says. Dr. Pollock believes that the most gratifying aspect of his career is having had the opportunity to mentor and nurture upcoming surgical oncology investigators. “They will certainly take our understanding much further than what I have been able to do myself,” he says. Asked to describe Dr. Pollock as a colleague, Randal Weber, MD, associate vice president for health care advancement at MD Anderson, says that Dr. Pollock is extremely thoughtful and incredibly insightful, has great leadership skills, and provides great guidance and mentorship. “He really understands the political landscape of a complex matrix organization, so he can help you with your own professional growth and development,” says Dr. Weber. “Dr. Pollock is a triple threat. He is an outstanding clinician, he is an accomplished and funded investigator from a research standpoint, and he is a great educator. Under his leadership, the surgical oncology program at MD Anderson became the preeminent one in the country.” Peter Shields, MD, deputy director of The Ohio State University Comprehensive Cancer Center, describes Dr. Pollock as extremely bright, creative, and very collegial. “When you meet the guy, you are a friend. He is very warm and open that way,” he says. “He has impacted countless numbers of people in science in many ways. Working with him is an absolute pleasure. He understands the balance between leadership and delegation.” “Dr. Pollock has been an incredible mentor. I worked closely with him, first as a research assistant, then as a graduate student and postdoctoral researcher, and now as a medical student,” says Abeba Zewdu, PhD, MD candidate, class of 2023, at The Ohio State University College of Medicine in Columbus. “Dr. Pollock dedicated countless hours to my education and growth. With his guidance, I learned to pursue my scientific curiosities, to function autonomously, to be resilient, and, most importantly, to live altruistically.”